Clinical Trials Logo

Dry Eye Syndromes clinical trials

View clinical trials related to Dry Eye Syndromes.

Filter by:

NCT ID: NCT01276223 Completed - Dry Eye Disease Clinical Trials

Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

Start date: February 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.

NCT ID: NCT01268735 Completed - Dry Eye Syndromes Clinical Trials

The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye

LIPCOF
Start date: April 2009
Phase: Phase 4
Study type: Interventional

Purpose To try to establish whether lid-parallel conjunctival folds (LIPCOF) can be influenced by increased lubrication with rewetting and lubricating eyedrops containing hydroxypropyl-guar, which has proven lubricating effect. Methods During summer and fall of 2009, 16 ophthalmologists from various regions of Croatia investigated the effect of topical therapy with lubricating eyedrops on the signs and symptoms of dry eye, with the special emphasis on lid-parallel conjunctival folds (LIPCOF). 229 patients were enrolled in the study. Results After 14 days of therapy with lubricating eyedrops containing hydroxypropyl-guar, statistically significant reduction of LIPCOF grade was observed, as well as the reduction of symptoms and other signs of dysfunctional tear syndrome (TBUT, Schirmer test, conjunctival hyperemia). Conclusion Results of this study have shown positive influence of lubricating eyedrops containing hydroxypropyl-guar on signs and symptoms of dysfunctional tear syndrome even after only 14 days of treatment. It is of particular interest that LIPCOF grade was statistically significantly decreased, pointing at increased friction and decreased ocular surface lubrication as possible causes of its appearance. Having this in mind, every clinician involved in dysfunctional tear syndrome treatment must also think about lubrication as integral part of treating this condition.

NCT ID: NCT01257607 Completed - Dry Eye Clinical Trials

Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Start date: November 2010
Phase: Phase 2
Study type: Interventional

The objective of this study is to compare the safety and efficacy of 1% MIM-D3 and 5% MIM-D3 to placebo for the treatment of the signs and symptoms of dry eye.

NCT ID: NCT01254201 Completed - Fibromyalgia Clinical Trials

The Pathogenesis of Idiopathic Dry Eyes

Start date: June 2008
Phase: N/A
Study type: Observational

Dry eyes are a very common complaint. In some patients, we can identify the reason for the dryness; however, in others the dryness has no clear cause. Dryness can lead to eye irritation, redness, and sometimes changes in vision. Fibromyalgia is a condition of chronic pain that is poorly understood but seems to have a component of altered sensory processing. People with fibromyalgia tend to complain of dry and irritated eyes at a higher rate than the general population. We plan to evaluate patients with dry eye symptoms for abnormalities in sensory processing and in their autonomic nervous system. We hope to learn about possible relationships between dry eye symptoms and fibromyalgia in order to better understand and treat these conditions.

NCT ID: NCT01252121 Completed - Dry Eye Syndrome Clinical Trials

Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline

Start date: October 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the ocular retention time of Systane Ultra compared to Hialid and saline.

NCT ID: NCT01250171 Completed - Dry Eye Clinical Trials

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This study assessed the effects of a single intravenous dose of secukinumab (AIN457) 10 mg/kg or canakinumab (ACZ885) 10 mg/kg on the signs and symptoms of dry eye. In addition, the pharmacokinetic, pharmacodynamic, and safety profiles of secukinumab and canakinumab were assessed. Blood samples were collected for the analysis of the effect of secukinumab and canakinumab on select biomarkers.

NCT ID: NCT01240382 Completed - Dry Eye Clinical Trials

Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Start date: n/a
Phase: Phase 3
Study type: Interventional

To investigate that the efficacy of 3% DE-089 ophthalmic solution (one drop at a time, 6 times daily, 4 weeks topical administration), in comparison to 0.1% sodium hyaluronate ophthalmic solution (0.1% HA) (one drop at a time, 6 times daily, 4 weeks topical administration), is at least non-inferior in the change in fluorescein staining score, and is superior in the change in Rose bengal score, in a multicenter, double-masked, parallel-group comparison study. Safety profile will likewise be compared.

NCT ID: NCT01239069 Completed - Dry Eye Clinical Trials

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Start date: November 2010
Phase: Phase 2
Study type: Interventional

Investigate the Safety and Efficacy of Two Concentrations of DE-110 Compared to Placebo for the Treatment of Dry Eye Disease

NCT ID: NCT01235234 Completed - Clinical trials for Keratoconjunctivitis Sicca

Trial of CF101 to Treat Patients With Dry Eye Disease

Start date: July 2011
Phase: Phase 3
Study type: Interventional

Eligible patients with dry eye will be treated with CF101 or placebo twice daily for 24 weeks. Disease activity will be assessed using evaluations of ocular surface integrity, tear production, and patient symptoms.

NCT ID: NCT01228929 Terminated - Healthy Clinical Trials

Non-invasive Ocular Surface Measurements Before and After Interventions

Start date: July 2010
Phase: N/A
Study type: Interventional

Objectively evaluate the ocular surface (pre-corneal tear film) of individuals prior to and after an intervention (such as a dry eye treatment, environmental change, artificial tear use, or contact lens wear) in a controlled-environmental chamber, over time using non-contact instruments.